Abstract:The virus severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, is the causative agent of the current COVID-19 pandemic. It possesses a large 30 kilobase (kb) genome that encodes structural, non-structural, and accessory proteins. Although not necessary to cause disease, these accessory proteins are known to influence viral replication and pathogenesis. Through the synthesis of novel infectious clones of SARS-CoV-2 that lack one or more of the accessory proteins of the virus, we have found that one of these accessory proteins, ORF8, is critical for the modulation of the host inflammatory response. Mice infected with a SARS-CoV-2 virus lacking ORF8 exhibit increased weight loss and exacerbated macrophage infiltration into the lungs. Additionally, infection of mice with recombinant SARS-CoV-2 viruses encoding ORF8 mutations found in variants of concern reveal that naturally occurring mutations in this protein influence disease severity. Our studies with a virus lacking this ORF8 protein and viruses possessing naturally occurring point mutations in this protein demonstrate that this protein impacts pathogenesis. The SARS-CoV-2 genome is composed of various genes that are responsible for replication of its genome, making virions as well as aiding the virus in replicating in host cells. The virus expresses several viral proteins during infection that are also thought to modulate the host response to the virus. Identifying the role of these proteins in infection and how they affect both viral replication and host response to infection is important to understand how SARS-CoV-2 causes disease. One of these proteins, ORF8, is mutated across many variant lineages and its function is unclear. Both the role of ORF8 in pathogenesis and how these mutations could be advantageous to viral fitness are unknown. We have found that mutations in ORF8 across variants recapitulate the loss of function phenotype of an ORF8 deletion virus and affect inflammation during infection. Mutations found in variants that cause a loss of function of ORF8 increase inflammation in our animal model suggesting that these mutations may play the same role in humans. Differences in ORF8 sequences of variants may significantly impact disease severity in humans and alter transmission kinetics so that mechanistic studies of its function are important to understand as SARS-CoV-2 continues to be spread.

Co-evolved ligands to ORF8. Could they reduce SARS-COV-2-excesive inflammation?

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator

SARS-CoV-2 ORF8 as a Modulator of Cytokine Induction: Evidence and Search for Molecular Mechanisms

SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression

Abrogation of ORF8–IRF3 binding interface with Carbon nanotube derivatives to rescue the host immune system against SARS-CoV-2 by using molecular screening and simulation approaches

Receptor-Based Pharmacophore Modelling of a series of ligands used as inhibitors of the SARS-CoV-2 virus by complementary theoretical approaches, molecular docking, and reactivity descriptors.

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

A computational study of cooperative binding to multiple SARS-CoV-2 proteins

Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT study

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

Drug repurposing for SARS-COV-2: A high-throughput molecular docking, molecular dynamics, machine learning, & ab-initio study

Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex

SARS-CoV-2 ORF8: A Rapidly Evolving Immune and Viral Modulator in COVID-19

In silico Drug Repurposing for COVID‐19: Targeting SARS‐CoV‐2 Proteins through Docking and Consensus Ranking

In Silico Discovery and Evaluation of Inhibitors of the SARS-CoV-2 Spike Protein–HSPA8 Complex Towards Developing COVID-19 Therapeutic Drugs

Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface

Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA

In Silico Discovery of Small Molecule Modulators Targeting the Achilles’ Heel of SARS-CoV-2 Spike Protein

Predicting inhibitors for SARS-CoV-2 RNA-dependent RNA polymerase using machine learning and virtual screening

Severe Acute Respiratory Syndrome Coronavirus 2 ORF8 Protein Inhibits Type I Interferon Production by Targeting HSP90B1 Signaling